Qiagen NV (LTS:0RLT)
€ 43.54 0 (0%) Market Cap: 9.16 Bil Enterprise Value: 9.58 Bil PE Ratio: 106.36 PB Ratio: 2.73 GF Score: 85/100

Qiagen NV at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 09:30PM GMT
Release Date Price: €42.44 (+2.84%)
Casey Rene Woodring
JPMorgan Chase & Co, Research Division - Research Analyst

Great. Thank you, everybody. Thanks for joining us today. Welcome to the JPMorgan Healthcare Conference. I'm Casey Woodring from the Life Science Tools and Diagnostics team here at JPM.

I'm pleased to be joined today by QIAGEN. We have CEO, Thierry Bernard, here for a presentation. We'll go through the presentation portion about 20, 25 minutes, then we'll jump to the Q&A session afterwards. So with that, Thierry, take it away.

Thierry Bernard
QIAGEN N.V. - CEO, MD & Member of Management Board

Thanks, Casey, and good afternoon. For those on the line, I mean, good evening. I hope not too many good night or good morning, but it's a pleasure to be with you once again. And thanks for your interest and attention on QIAGEN.

It's my fifth year now presenting together with you on QIAGEN. And today, I'm going to spend time explaining why what I consider to be a unique positioning of our company is helping us delivering for the last years, but especially also in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot